References
- Powell FC, Su WP, Perry HO. Pyoderma gangrenosum: classification and management. J Am Acad Dermatol. 1996;34:395–409
- Marzano AV, Ishak RS, Saibeni S, et al. Autoinflammatory skin disorders in inflammatory bowel diseases, Pyoderma gangrenosum and Sweet's syndrome: a comprehensive review and disease classification criteria. Clin Rev Allergy Immunol. 2013;45:202–10
- Thrash B, Patel M, Shah KR, et al. Cutaneous manifestations of gastrointestinal disease: part II. J Am Acad Dermatol. 2013;68:211.e1–33; quiz 244–6
- Levitt MD, Ritchie JK, Lennard-Jones JE, Phillips RK. Pyoderma gangrenosum in inflammatory bowel disease. Br J Surg. 1991;78:676–78
- Miller J, Yentzer BA, Clark A, et al. Pyoderma gangrenosum: a review and update on new therapies. J Am Acad Dermatol. 2010;62:646–54
- Reichrath J, Bens G, Bonowitz A, Tilgen W. Treatment recommendations for Pyoderma gangrenosum: an evidence-based review of the literature based on more than 350 patients. J Am Acad Dermatol. 2005;53:273–83
- Brooklyn TN, Dunill MG, Shetty A, et al. Infliximab for the treatment of Pyoderma gangrenosum: a randomized, double blind, placebo controlled trial. Gut. 2006;55:505–9
- Regueiro M, Valentine J, Plevy S, et al. Infliximab for treatment of Pyoderma gangrenosum associated with inflammatory bowel disease. Am J Gastroenterol. 2003;98:1821–6
- Reguiaï Z, Grange F. The role of anti-tumor necrosis factor-alpha therapy in Pyoderma gangrenosum associated with inflammatory bowel disease. Am J Clin Dermatol. 2007;8:67–77
- Zold E, Nagy A, Devenyi K, et al. Successful use of adalimumab for treating fistulizing Crohn’s disease with Pyoderma gangrenosum: two birds with one stone. World J Gastroenterol. 2009;15:2293–5
- Cinotti E, Labeille B, Perrot JL, et al. Certolizumab for the treatment of refractory disseminated Pyoderma gangrenosum associated with rheumatoid arthritis. Clin Exp Dermatol. 2014;39:750–1